Information Provided By:
Fly News Breaks for March 6, 2019
FATE
Mar 6, 2019 | 08:59 EDT
Wells Fargo analyst Jim Birchenough raised his price target for Fate Therapeutics to $24 from $18 following review of Q4 progress and 2019 outlook for the company's novel cell therapy platform and pipeline of iPSC derived therapeutics for cancer. The analyst reiterates an Outperform rating on the shares.
News For FATE From the Last 2 Days
FATE
Apr 18, 2024 | 17:52 EDT
Check out this evening's top movers from around Wall Street, compiled by The Fly. HIGHER AFTER EARNINGSMetropolitan... To see the rest of the story go to thefly.com. See Story Here
FATE
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.